Ablelite Pediatric Device Clinical Study

NCT04308447 — Not applicable, Unknown, 20 participants, AbiliTech Medical Inc.

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT04308447
StatusUnknown
PhaseNot applicable
Study typeInterventional; na, single group, masking: none, treatment
Enrollment20 (Estimated)
SponsorAbiliTech Medical Inc. (Industry); collaborators: Gillette Children's Specialty Healthcare, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ConditionsMuscular Dystrophies
InterventionsAbleLite (Device)
Datesstart 2020-07-01 (estimated), primary completion 2020-12-31 (estimated), completion 2021-01-31 (estimated), first posted 2020-03-16, last updated 2020-03-16

Related Papers Related Patents Related Grants Related Experts
All trials for Muscular Dystrophies All trials of AbleLite

-Summary

The primary objective of the AbleLite early feasibility study is to evaluate the function of the upper limbs of participants diagnosed with neuromuscular disorders as children, with and without use of the Abilitech AbleLite device in the clinic and home environments. Functional outcomes will include documenting active range of motion and the ability to perform activities of daily living (ADLs) using the standardized Canadian Occupational Performance Measure (COPM) and the Role Evaluation of Activities of Life (REAL) assessments. Secondary objectives are to assess the safety record and report on adverse events (AEs) and parameters related to device usage, including device usage time and the time required to don/doff the device.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
AbleLiteExperimentalDevice: AbleLiteThe AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
  • AbleLite (Device): The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.

+Outcome measures

Primary outcomes

  • Canadian Occupational Performance Measure (COPM) [Change from Baseline before device intervention (30 days), and after device intervention (60 days)]: The Canadian Occupational Performance Measure is an evidence-based outcome measure designed to capture a client's self-perception of performance in everyday living, over time.
  • Roll Evaluation of Activities of Life (REAL) assessment [Change from Baseline before device intervention (30 days), and after device intervention (60 days)]: The REAL is an instrument to help professionals assess a child's ability to care for themselves at home, at school and in the community.

+Eligibility

Sex: All, ages: 9 Years to 18 Years

Inclusion Criteria:

1. Subjects between 9 and 18 years of age, with pediatric onset of neuromuscular conditions that cause quadriparesis
2. MMT score of 1-3 in the elbow, wrist and hands, and an MMT score of 2- to 3 in the shoulder
3. Ability of subject to raise their forearm off of their lap or laptray
4. Willingness to comply and participate with the study protocol and attend the study sessions
5. Ability to communicate verbally and respond to questions and commands
6. Ability to provide informed consent
7. Selected for participation based on investigator discretion

Exclusion Criteria:

1. Use of ventilator
2. Open wounds or chronic pressure sores on upper extremities, neck, back or torso
3. Significantly unstable upper extremity joints
4. Unhealed bone fractures in the upper extremities
5. Active rotator cuff tear, grade 2 or 3
6. Surgical fixations limiting full passive range of motion
7. Uncontrolled upper-limb spasticity that significantly limits normal range of motion
8. Uncontrollable pain in the neck, shoulders or upper limbs
9. Ability to fully raise both hands simultaneously above their head with ease
10. Lack passive shoulder abduction of 120 degrees
11. Lack 90 degrees of passive elbow extension
12. Unable to follow instructions
13. Exhibit significant behavioral problems
14. Inability to provide consent

+Funding

NIH grants: R44HD089789